Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC
In Partnership With:
Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer
Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer (CRC).
Although there have been many advances in the treatment landscape of BRAF-mutant CRC, there is still room for improvement, says Kopetz. Currently, a promising triplet therapy of BRAF, MEK, and EGFR inhibitors is being studied in this population.
In the randomized phase III BEACON study, the triplet of binimetinib, encorafenib, and cetuximab (Erbitux), is being evaluated in patients with metastatic BRAF V600E CRC whose disease has progressed after 1 or 2 prior regimens. Kopetz says that this combination demonstrated a promising response rate of about 48%, with a median progression-free survival of about 8 months.
